Program
olokizumab
Also written as “CDP6038”, “Olokizumab” and “OKZ q4w”.
Its studies are mostly in Arthritis, Rheumatoid · COVID-19 · Polymyalgia Rheumatica · Arthritis, Juvenile · Lung Diseases, Interstitial, led by 2 companies.
Drug pageOlokizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| R-Pharmits history only | 113 open or running | phase 3since Apr 29, 2016 | Apr 29, 2016 | Apr 9, 2027phase 3 · NCT06440746 |
| UCB | 80 open or running | phase 2since Nov 4, 2009 | Nov 4, 2009 | none ahead |
Also a collaborator on its studies: Keystat, Exacte Labs, Data Management 365, IQVIA Pvt., Quintiles, K-Research, Cromos Pharma and Covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of UCB only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2009First study: phase 2 study in ArthritisFirst studyNCT01009242 · 40 enrolled · United States, Germany
- Nov 15, 2010Phase 2 study in Arthritis, RheumatoidNCT01242488 · 221 enrolled · United States, Belgium, United Kingdom
- Dec 16, 2010Phase 1 study in Healthy VolunteersNCT01262794 · 20 enrolled · United Kingdom
- Jan 11, 2011Phase 1 study in PharmacokineticsNCT01276119 · 67 enrolled · Germany
- Feb 14, 2011Phase 2 study in Arthritis, RheumatoidNCT01296711 · 190 enrolled · United States, Belgium, United Kingdom
- Oct 27, 2011Phase 2 study in Arthritis, RheumatoidNCT01463059 · 119 enrolled · Japan, Korea, Republic of, Taiwan
- Feb 10, 2012Phase 2 study in Arthritis, RheumatoidNCT01533714 · 103 enrolled · Japan, Korea, Republic of, Taiwan
- Jul 3, 2012Phase 2 study in Crohn DiseaseNCT01635621
TargetBeta
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (IL-6), ”NCIt, by rule
“Interleukin-6 inhibitor”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| clazakizumab | CSL | phase 3 | 10 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
All 8 UCB leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01635621Crohn Disease | 2 | Withdrawn | Aug 2013 | 0 |
| NCT01533714Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan | 2 | Terminated | Nov 27, 2013 | 103 |
| NCT01463059Arthritis, Rheumatoid · Japan, Korea, Republic of, Taiwan | 2 | Completed | Feb 2013 | 119 |
| NCT01296711Arthritis, Rheumatoid · United States, Belgium, United Kingdom | 2 | Terminated | May 1, 2013 | 190 |
| NCT01276119Pharmacokinetics · Germany | 1 | Completed | Oct 2009 | 67 |
| NCT01262794Healthy Volunteers · United Kingdom | 1 | Completed | Sep 2011 | 20 |
| NCT01242488Arthritis, Rheumatoid · United States, Belgium, United Kingdom | 2 | Completed | Jun 2012 | 221 |
| NCT01009242Arthritis · United States, Germany | 2 | Completed | Sep 2010 | 40 |
How it is read
Names in the registry
- “CDP6038”, 13 entries
- “Olokizumab”, 5 entries
- “OKZ q4w”, 2 entries
- “CDP6038 (olokizumab)”, 2 entries
- “Olokizumab 64 mg”, 2 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 10 studies
- COVID-19, 3 studies
- Polymyalgia Rheumatica, 1 study
- Arthritis, Juvenile, 1 study
- Lung Diseases, Interstitial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.